Top Health Tech Companies (10,000+)

Strong Revenue Growth: Reported revenue has been rising at a double‑digit pace across fiscal 2025 and the first half of 2026, with both Q1 and Q2 showing solid year‑over‑year increases. Management also raised full‑year 2026 revenue guidance, indicating confidence in continued expansion.

Profitability: Profitability is strong, with adjusted EBITDA growing year over year and margins holding in the low‑40s through fiscal 2025 and recent quarters. The company also reported positive net income and healthy cash generation.

Customer Loyalty & Retention: Net revenue retention remained expansionary and the number of larger clients increased year over year. Subscription revenue grew faster than total revenue in recent periods, suggesting deeper adoption within the existing base.

Strong Revenue Growth: Revenue is reported to have surpassed the $100 million annual mark with continued year-over-year gains. Feedback suggests momentum is reinforced by growth in newer verticals such as education and hospitality.

Market Expansion: The company extended its footprint from North America into the UK and Ireland and broadened placements beyond offices into campuses, hotels, gyms, warehouses, and other venues, while scaling to more than 6,000 customers. Feedback suggests international entry and vertical diversification are driving a larger installed base and usage milestones such as surpassing one billion single-use containers avoided.

Product Line Growth: The offering advanced from smart water coolers to a connected beverage platform, adding functional enhancements and a better-for-you soda line alongside new countertop hardware. Feedback suggests the expanded menu increases relevance across more locations and upsell potential within existing accounts.

Strong Revenue Growth: Revenue is depicted as rising dramatically, including an increase from $3.6M in 2021 to $617.4M in 2024 and subsequent commentary citing a roughly $1B run rate.

Investor Backing & Capital Strength: Capital access appears robust, highlighted by a $150M Series D in 2026 at an approximately $3B valuation and total funding near $328M from prominent investors.

Market Expansion: Geographic and channel reach is expanding, with 26,000+ clinicians across all 50 states, 125+ insurance partners (including Medicare and Medicaid), and movement into employer and health‑system partnerships.

Strong Market Position & Advantage: Adoption spans 1,300+ biotechnology organizations with usage reported across more than half of the top 50 biopharma companies, signaling durable positioning in life‑sciences R&D software. Multiple sources characterize the platform as a leading life‑sciences R&D cloud used by both startups and major enterprises.

Product Line Growth: The company continues to launch and expand major offerings, including Benchling AI, antibody‑discovery capabilities, automation/analysis tools, and extensions into new scientific workflows such as small‑molecule chemistry. Acquisitions like PipeBio further broaden capability depth in biologics and related R&D domains.

Innovation-Driven Growth: AI is a clear growth vector, with reports that 500 biotech companies used Benchling AI in its first year and the product subsequently reached general availability. Team acquisitions (e.g., ReSync Bio and Sphinx Bio) and partnerships (e.g., with Anthropic) underscore a deliberate push to embed advanced models into scientific workflows.

Strong Revenue Growth: Top-line revenue is reported to have grown strongly on a multi-year basis through 2023, with additional indications of continued increases into 2025–2026. This provides the clearest quantitative signal of momentum for a private company with limited disclosures.

Market Expansion: The provider network and product footprint have broadened, including new launches such as programmatic access and a consumer health media offering alongside partnerships that extend reach. These moves show growth beyond core point-of-care screens into adjacent adtech and consumer channels.

Investor Backing & Capital Strength: Advent International’s 2025 agreement to acquire the company and continued investment signal substantial sponsor support for scaling. Such backing typically underwrites further network growth and product innovation.

Market Expansion: International footprint is described as rapidly scaling, with the oncology research network tripling year over year and later noted as nearly 70% ex‑U.S. growth across the UK, Germany, Japan, and new regions like Scotland. Point‑of‑care reach is also portrayed as expanding, with 1,600+ sites of care and increases from earlier baselines.

Product Line Growth: New offerings include the launch of Flatiron Telescope and multiple AI-enabled datasets, alongside expansions of major assets such as the NSCLC Panoramic dataset. Additional capabilities like LLM-based data extraction and new hematology datasets indicate broader, monetizable product breadth.

Strategic Partnerships: Collaborations are highlighted with organizations such as NCCN, Quest Diagnostics, Candid Health, TailorMed, and DeepScribe, as well as a multi‑year partnership alongside the Paradigm transaction. Engagements with 20+ global oncology drug developers and academic institutions reinforce a partnership‑driven operating model.

Strong Revenue Growth: Independent estimates indicate revenue roughly doubled in 2024 to around $471M annualized, pointing to rapid top-line expansion. While privately held and unaudited, the trajectory across 2023–2025 is characterized by accelerated scaling.

Market Expansion: Covered therapy was extended to all 50 states plus Washington, D.C. in 2024, with psychiatry rolled out nationwide by 2025. The network grew from 10,000+ providers in 2024 to 23,000+ by 2026, broadening reach and utilization.

Strategic Partnerships: An Amazon Health program listing and other distribution channels increased visibility and access. A cited OptumCare collaboration saw referrals grow by triple digits year over year, signaling traction in enterprise pathways.

Strong Revenue Growth: Top-line growth is portrayed as rapid, with claims of seven-figure to near eight-figure ARR and sharp recent acceleration. Company materials also describe an eightfold scale-up alongside broader adoption in hospitals.

Investor Backing & Capital Strength: Capital support appears robust, with backing from Y Combinator and institutional investors such as Oak HC/FT and Norwest, plus reports of a recent Series A and tens of millions raised. This financing base is positioned to fund continued product and market expansion.

Market Expansion: Hospital deployments are expanding, with reports of being live across dozens of facilities and plans to scale significantly. Usage by large numbers of clinical staff and work with top health systems indicate a widening footprint.

Market Expansion: Patient reach rose from 22M in 2022 to 25M in 2023 and 50M by January 2025, alongside new wins such as Sanford Health and multiple physician groups adopting the platform. Kora was also adopted by 10 provider organizations within its first year, reinforcing broader commercial uptake.

Product Line Growth: Cedar expanded from payments/billing into affordability, AI support, and the Kora AI agent in 2025–26, later broadening into the multi‑agent Kora Platform. Additional launches like Cedar Cover extended capabilities into Medicaid enrollment, renewals, and denials resolution.

Innovation-Driven Growth: AI‑driven workflows are central, with Kora handling roughly 400,000 patient calls in its first year and continued rollout of Cedar Intelligence in 2026. Recognition and ongoing AI feature releases signal a strategy centered on technology-led growth in healthcare financial workflows.

Investor Backing & Capital Strength: Funding is described as including a $30M Series B led by Andreessen Horowitz, bringing total backing to about $50M, signaling strong capital support for scaling. Investor commentary highlights conviction in Camber’s execution and claims-data advantage.

Market Expansion: Operations are reported to have broadened from an initial behavioral-health focus into additional care verticals and across all 50 states, alongside rising claims volume and provider reach. Company materials cite millions of claims processed and coverage of large billable amounts.

Strong Hiring & Retention: Hiring activity is ongoing, with the company described in the 51–200 employee range and noting its biggest hiring quarter in 2025. Open roles and expansion of enterprise go-to-market roles indicate continued team scaling.

Strong Revenue Growth: Optum’s consolidated revenue expanded from $253.0B in 2024 to $270.6B in 2025, indicating continued top-line growth. Multi‑year reporting also highlights ongoing increases at the consolidated level even as segment performance diverges.

Diversified Revenue Streams: Performance is spread across three businesses, with Optum Rx delivering substantial gains, Optum Insight growing modestly, and Optum Health contracting. This mix shows pharmacy and technology services helping sustain overall scale despite softness in care delivery.

Cost & Operational Efficiency: Operating performance improved in 2026 as Optum’s operating income rose year over year to about $4B in Q2 alongside reported gains in technology and clinical operations. UnitedHealth also raised its 2026 adjusted EPS outlook, signaling confidence in execution.

Market Expansion: Adoption appears to have increased from 19,000+ hospitals in June 2023 to 23,000+ currently, indicating continued penetration of the U.S. veterinary market. The platform is also described as powering purchasing infrastructure for the majority of several practice types nationwide.

Product Line Growth: The offering has expanded from a price-comparison tool into a broader procurement ecosystem spanning distributors, manufacturers, and diagnostic labs, with a catalog covering 99.9% of products veterinarians use. This evolution points to a shift toward comprehensive procurement infrastructure rather than a single-point solution.

Strong Market Position & Advantage: A 23,000+ hospital installed base and a supplier-side marketplace marketed as access to 23,000+ clinics suggest reinforcing network effects. Monetization on the supplier/manufacturer side and corporate capabilities further underscore centrality in the purchasing workflow.

Investor Backing & Capital Strength: Investor backing is highlighted by seed and Series A rounds led by Accel and participation from notable angels, bringing total funding to roughly $19.7M. Feedback suggests this capital has supported team expansion and product development.

Market Expansion: Customer additions include fast-growing tech companies like Mintlify, Equals, and Braintrust, with accounts noting switches from legacy systems such as QuickBooks and NetSuite. Feedback suggests the company is extending its presence within the AI-native accounting niche for startups.

Innovation-Driven Growth: The platform combines an AI-native general ledger with managed services, continuous reconciliation, and tools like Prism for real-time financial exploration. Feedback suggests this differentiated product approach underpins traction among modern software companies.

Strong Revenue Growth: Revenue is reported to have grown 4× in 2023, more than 300% in 2024, and then doubled again in 2025, indicating sustained acceleration. Company communications consistently point to multi‑year, triple‑digit expansion across successive periods.

Investor Backing & Capital Strength: Capital raised includes a $47M Series B in 2024 and a $72M Series C in 2025, bringing total funding to $162M. This level of financing from institutional and strategic investors signals ample resources to support scale.

Strategic Partnerships: Partnerships are described with 7–8 of the top 10 U.S. life insurers and additional organizations such as Prudential, Principal, and Aflac. This enterprise-led distribution has extended access to tens of millions of policyholders and employees.

Strong Revenue Growth: TechCrunch reported that revenue increased six-fold year over year as of May 2025, indicating rapid top-line acceleration.

Market Expansion: The company expanded from 5 states in 2023 to 18 states in 2025 and announced nearly 25 states by February 2026, pointing to broadening geographic coverage.

Investor Backing & Capital Strength: The company closed a $55 million Series B in May 2025, bringing total funding to about $125 million. The round was led by General Catalyst with participation from Andreessen Horowitz, GV, and Accel, underscoring access to capital.

Market Expansion: Reported enrollments of roughly 250,000 in 2025 and a broker base exceeding 10,000 point to a rapidly widening operating footprint. AEP 2025 production metrics and tens of thousands of contracts processed further suggest the platform is scaling beyond its 2024 funding milestone.

Investor Backing & Capital Strength: A $25M Series B in January 2024, reportedly at a significant valuation step-up, underscores access to growth capital. Independent listings also record total funding in the high-$30Ms range, reinforcing external validation of capitalization.

Strong Hiring & Retention: Headcount reportedly expanded from around 40 to roughly 130 by 2025, and current postings include senior roles across revenue operations, engineering, product, and agent/customer experience. Active requisitions signal continued investment in growth infrastructure.

Strong Revenue Growth: Management stated consistent double‑digit expansion with revenue growing more than 40% in the prior year, alongside significant market‑share gains. Plans to double headcount and a move into a 3× larger office reinforce the current growth trajectory.

Product Line Growth: The platform has expanded from core EHR/eMAR into CRM, billing and payments, occupancy/revenue tools, BI, family engagement, and AI (Ask ALIS), and added AI‑enabled dementia/behavioral‑care capabilities via its first acquisition. This broader suite increases revenue opportunity per customer and signals scaling beyond a single‑product footprint.

Market Expansion: The company reports serving assisted living, memory care, independent living, and behavioral‑care communities in more than 40 states, with usage across 3,000+ communities and 200,000 residents. An active partner ecosystem and 130+ integrations also indicate widening reach.

Investor Backing & Capital Strength: Recent financing includes a $50 million Series D anchored by Boehringer Ingelheim, following a Series C in 2025 and prior debt financing, indicating sustained access to strategic capital. The transfer of CT-155 commercialization responsibility alongside dedicated commercial funding further underscores capital support aligned with near-term growth plans.

Strategic Partnerships: Collaborations with major pharmaceutical companies such as Otsuka and Boehringer Ingelheim, alongside agreements with Indivior and Ultrahuman, reflect deepening partner engagement in development and commercialization. These alliances have produced FDA-authorized products and structured milestone and royalty pathways that reinforce external validation.

Product Line Growth: Multiple FDA authorizations (Rejoyn for MDD and CT-132 for migraine), the acquisition of AspyreRx, and an expanded pipeline spanning psychiatry, neurology, and cardiometabolic disease point to a broader, more mature portfolio. Positive Phase 3 results and commercialization preparations for CT-155 add momentum to this expansion.

Investor Backing & Capital Strength: Capital raising has accelerated, including a $372M Series D in 2024 with total funding reported in the hundreds of millions to expand the pipeline and AI platform. Valuation has stepped up from roughly $1.04B (2021) to about $1.48B post‑money (2024), signaling strengthened private‑market positioning.

Strategic Partnerships: Partnerships are expanding, highlighted by a collaboration with Sanofi and OpenAI to build AI software for drug development and increased business‑development capacity via Entrepreneurs in Residence. Engagements with large pharma partners, including Sanofi, underscore growing external validation and deal flow.

Product Line Growth: The pipeline is broadening through multiple in‑licenses—such as an anti‑CD226 program, a CNS‑penetrant TYK2 inhibitor, and a miR‑124 activator—and progression to first‑in‑human dosing of BLKR201 in 2026. Stated plans to reach 10–15 assets over 3–5 years align with recent portfolio expansion and clinical advancement.

Strong Revenue Growth: Company-reported results indicate 34% year-over-year software growth in 2024, alongside earlier periods of 100% YoY elluminate software growth in 2022 and 50% in 2021. These signals point to sustained momentum in the software business.

Market Expansion: The organization added 20 net-new clients in 2024 and more than 20 in 2025, with its footprint among top global pharma expanding from 16 to 18 of the world’s top 50 companies. This reflects a widening customer base across large enterprise accounts.

Investor Backing & Capital Strength: A September 2024 majority investment by GI Partners—described as a growth investment—with previous investor Summit Partners retaining a minority stake indicates strong institutional support. Subsequent expansion of the executive team aligns with funding to drive the next phase of growth.